(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-1.03%) $82.99
(-1.16%) $1.619
(-0.56%) $2 334.10
(-0.91%) $27.29
(0.41%) $925.90
(-0.12%) $0.934
(-0.06%) $11.02
(-0.18%) $0.799
(0.00%) $92.17
2 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 4.95%
Live Chart Being Loaded With Signals
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures...
Stats | |
---|---|
Šios dienos apimtis | 4.29M |
Vidutinė apimtis | 3.62M |
Rinkos kapitalizacija | 8.58B |
EPS | £0 ( 2024-02-27 ) |
Kita pelno data | ( £0 ) 2024-05-01 |
Last Dividend | £18.38 ( 2023-03-30 ) |
Next Dividend | £0 ( N/A ) |
P/E | 40.88 |
ATR14 | £0.504 (0.05%) |
Tūris Koreliacija
Smith & Nephew plc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Smith & Nephew plc Koreliacija - Valiuta/Žaliavos
Smith & Nephew plc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | £5.55B |
Bruto pelnas: | £3.82B (68.82 %) |
EPS: | £0.300 |
FY | 2023 |
Pajamos: | £5.55B |
Bruto pelnas: | £3.82B (68.82 %) |
EPS: | £0.300 |
FY | 2022 |
Pajamos: | £5.22B |
Bruto pelnas: | £3.68B (70.47 %) |
EPS: | £0.250 |
FY | 2021 |
Pajamos: | £5.21B |
Bruto pelnas: | £3.67B (70.40 %) |
EPS: | £0.598 |
Financial Reports:
No articles found.
Smith & Nephew plc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
£12.91 (N/A) |
£0 (N/A) |
£18.38 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | £3.45 | 1993-05-10 |
Last Dividend | £18.38 | 2023-03-30 |
Next Dividend | £0 | N/A |
Payout Date | 2023-05-17 | |
Next Payout Date | N/A | |
# dividends | 64 | -- |
Total Paid Out | £440.59 | -- |
Avg. Dividend % Per Year | 1.26% | -- |
Score | 4.16 | -- |
Div. Sustainability Score | 8.49 | |
Div.Growth Potential Score | 4.99 | |
Div. Directional Score | 6.74 | -- |
Year | Amount | Yield |
---|---|---|
1993 | £0 | 0.00% |
1994 | £0 | 0.00% |
1995 | £0 | 0.00% |
1996 | £0 | 0.00% |
1997 | £0 | 0.00% |
1998 | £0 | 0.00% |
1999 | £0 | 0.00% |
2000 | £0 | 0.00% |
2001 | £0 | 0.00% |
2002 | £0 | 0.00% |
2003 | £0 | 0.00% |
2004 | £0 | 0.00% |
2005 | £0 | 0.00% |
2006 | £0 | 0.00% |
2007 | £0 | 0.00% |
2008 | £0 | 0.00% |
2009 | £0 | 0.00% |
2010 | £0 | 0.00% |
2011 | £0 | 0.00% |
2012 | £0 | 0.00% |
2013 | £0 | 0.00% |
2014 | £0 | 0.00% |
2015 | £0 | 0.00% |
2016 | £0 | 0.00% |
2017 | £0 | 0.00% |
2018 | £26.91 | 1.93% |
2019 | £28.49 | 1.99% |
2020 | £29.73 | 1.62% |
2021 | £27.12 | 1.73% |
2022 | £31.31 | 2.40% |
2023 | £18.38 | 1.64% |
2024 | £0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
ROOF.L | Dividend Knight | 2023-08-03 | Quarterly | 3 | 1.92% | |
HHV.L | Dividend Knight | 2023-06-29 | Semi-Annually | 19 | 3.83% | |
AVON.L | Dividend Junior | 2023-08-10 | Semi-Annually | 33 | 1.69% | |
VCAP.L | Dividend Knight | 2023-09-14 | Semi-Annually | 4 | 3.56% | |
MRCH.L | Dividend King | 2023-07-06 | Quarterly | 53 | 3.07% | |
DLN.L | Dividend Knight | 2023-09-07 | Semi-Annually | 32 | 1.77% | |
SHG.L | Dividend Knight | 2023-11-02 | Semi-Annually | 4 | 0.91% | |
IHP.L | Dividend Knight | 2023-06-08 | Semi-Annually | 7 | 1.08% | |
BOCH.L | Dividend Junior | 2023-05-04 | Insufficient data to determine frequency | 2 | 1.10% | |
OCN.L | Dividend Knight | 2023-05-18 | Annually | 19 | 3.96% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0474 | 1.500 | 9.05 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0263 | 1.200 | 9.12 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0503 | 1.500 | -0.552 | -0.828 | [0.1 - 1] |
payoutRatioTTM | 1.243 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 1.775 | 0.800 | 6.13 | 4.90 | [1 - 3] |
quickRatioTTM | 0.569 | 0.800 | -1.359 | -1.087 | [0.8 - 2.5] |
cashRatioTTM | 0.133 | 1.500 | -0.372 | -0.558 | [0.2 - 2] |
debtRatioTTM | 0.309 | -1.500 | 4.85 | -7.28 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.695 | 2.00 | 9.77 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.207 | 2.00 | 9.90 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.591 | -1.500 | 7.64 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.701 | 1.000 | 1.644 | 1.644 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.123 | 1.000 | 9.54 | 9.54 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.197 | 1.000 | -0.0159 | -0.0159 | [0.2 - 2] |
assetTurnoverTTM | 0.556 | 0.800 | 9.63 | 7.70 | [0.5 - 2] |
Total Score | 8.49 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 40.78 | 1.000 | 5.98 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0503 | 2.50 | -0.355 | -0.828 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.207 | 2.00 | 9.93 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.85 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.695 | 2.00 | 9.77 | 10.00 | [0 - 30] |
payoutRatioTTM | 1.243 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.110 | 1.000 | 9.76 | 0 | [0.1 - 0.5] |
Total Score | 4.99 |
Smith & Nephew plc
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.